It is always GREAT to see the partnership between my old colleagues @Karyopharm Therapeutics Inc. and The Leukemia & Lymphoma Society. The LLS is near and dear to heart from Celgene Pharma - I have supported them for years. Well done James Accumanno & Brian Austad! I think I see Elhan Webb, CFA there too. All the folks at this event are excellent & "Keepers". We cannot afford to lose them from KaryoPharm 3.0 (the 3rd Reboot)! Folks, we have an opportunity to hire a new Chief Financial Officer from Takeda Oncology - we gotta SEIZE the DAY! CARPE FRICKIN' DIEM! CANCER PATIENTS ARE WAITING!
Doctor DueDiligence: why was the CEO not at this Boston LLS event? I see other KaryoPharmers - KPTI shareholders like us pay for these donations (LLS is KEY). Uncle Rolli & I love the LLS. They help many patients & families.
I will soon be unleashed to buy or sell more KPTI shares. My SEC lawyers confirmed that we are good to go as long as Uncle Rolli & I stay UNDER 5%.
I will be releasing my new org chart for KPTI for all investors - Richard is no longer on it or my BOD. He can keep his current 1.3M shares - he has not bought back any for a reason (he DOES NOT BELIEVE IN HIS OWN COMPANY). We do not need Richard's salary. PERIOD!
Uncle Rolli Greer and I will quickly realize $20-30M in annual savings for KPTI with our plans to fix the Business, focus on TRULY preparing for the launch by moving Sohanya to Chief Pipeline Officer (CPO), and making Steve Ferrari the Chief Operating Officer with HR, IT, Brian's team, & Medical Operations (Veeva & otherwise) directly into the new COO.
On my org chart: I have either Reshma or Sohanya as my new CEO. I think that Reshma is ready now - Sohanya is her "backup" to calm other investors.
Stuart stays as Chief Development Officer as long as we can restart the Phase 2 glioblastoma program for XPOVIO® (selinexor) HCP.
We can also save money by consolidating Development under my new CMO Tomer Mark (who is excellent).
This way: Tomer becomes the new Chief Medical Officer (CMO) & we have a bench in case Reshma or Sohanya leaves. Reshma, Sohanya, Tomer are SUPERSTARS.
Richard has hired three potential CEOs: Reshma, Sohanya, Stuart. Richard needs to GET OUT THE WAY. They are LEADERS.
Uncle Rolli & I have a plan to fix the company, save Boston Jobs, & ensure that we see if selinexor - which penetrates the blood-brain barrier - can help Cure Glioblastoma via a $25M Phase 2 study.
I am prepared to replace the worst Director on the BOT soon.
The stock has gone from $24 to 87 CENTS A SHARE! How are institutional & retail investors like me & nonbinary Uncle Rolli NOT furious about this?
What the Heck, guys!
If Richard does not STEP DOWN AS CEO SOON, then Uncle Rolli and I will move our investment dollars elsewhere.
Pineapple Energy, RedHill Biopharma Ltd., & Tiziana Life Sciences appreciate our expertise - even if KPTI does not.
BR,
~Jeff Conroy
Global HC Analytics LLC
jconroy@theghca.com
Manager @ Optum Advisory | Optimizing Portfolio Performance & Driving Impactful Results
4moGrateful for your research on this, Helen and team. The financial impact of cancer-related care is astronomical. I’ll never forget the OOP monthly costs a family member had for Gleevec. It was outrageous. Prior to the elimination of their Patient Access division, I worked as the MN/WI/SD Patient Access Manager for LLS. A significant focus of my work was financial support for families. I distinctly remember one member who had relapsed calling me to ask for advice on taking a second mortgage out so they could afford a stem cell transplant. That conversation will always stick with me.